← Leaderboards
Walter Stadler
University Of Chicago
$4,866,327
Attributed
$4,866,327
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2011–15$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$4,866,327 · 2
By mechanism
N01$4,866,327 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Chicago
Same institution · by research overlap
- Viresh H. Rawal$5,969,537
- Aaron Esser-Kahn$13,698,058
- Mark J Ratain$26,736,475
- Anthony A Kossiakoff$25,521,601
- William Dean Wulff$3,040,002
Others in their field
Top investigators on “Contracts”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,154,975,474
- Leonard Freedman · Leidos Biomedical Research, Inc.$811,365,654
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Bambra Strokes · Ppd Development Lp$526,656,217
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
Research focus
ContractsTherapeutic DevelopmentClinical TrialsData ReportingPhase 2 StudyProtocols DocumentationCombined Modality TherapyClinically RelevantResearch PersonnelMolecular TargetDrug DevelopmentDevelopmental Therapeutics ProgramToxic EffectDrug IndustryImage AnalysisMalignant NeoplasmsNew AgentsNormal Tissue MorphologyOrganPatient PopulationPharmacodynamicsPharmacologyRadiation TherapyResearch Design
Grant awards (6)
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$258,585
N01 · FY2015 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,150,388
N01 · FY2014 · CA · contact PI
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$693,703
N01 · FY2013 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$1,433,232
N01 · FY2012 · CA · contact PI
Early Therapeutics Development with Phase II Emphasis$856,723
N01 · FY2011 · CA · contact PI
TAS::75 0849::TAS EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS$473,696
N01 · FY2011 · CA · contact PI